Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$226.31
-0.5%
$216.12
$163.81
$244.81
$399.80B0.516.48 million shs5.40 million shs
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$43.63
-0.4%
$46.18
$42.96
$63.33
$88.81B0.3313.58 million shs11.79 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$84.11
-0.7%
$83.67
$73.31
$111.20
$210.08B0.3714.90 million shs9.13 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.51%-1.81%+4.94%+20.29%+17.02%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+0.62%-1.82%-5.20%-7.09%-16.81%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.95%-3.21%+2.35%+2.88%-22.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$226.31
-0.5%
$216.12
$163.81
$244.81
$399.80B0.516.48 million shs5.40 million shs
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$43.63
-0.4%
$46.18
$42.96
$63.33
$88.81B0.3313.58 million shs11.79 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$84.11
-0.7%
$83.67
$73.31
$111.20
$210.08B0.3714.90 million shs9.13 million shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
-0.51%-1.81%+4.94%+20.29%+17.02%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
+0.62%-1.82%-5.20%-7.09%-16.81%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.95%-3.21%+2.35%+2.88%-22.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.71
Moderate Buy$231.902.47% Upside
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.33
Hold$57.1430.97% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.29
Hold$105.0024.84% Upside

Current Analyst Ratings Breakdown

Latest MRK, BMY, and ABBV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/14/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Erste Group Bank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold
10/14/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/13/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
10/13/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
10/13/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$84.00 ➝ $95.00
10/10/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$231.00 ➝ $284.00
10/9/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetOverweight$250.00
10/8/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
10/8/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
10/3/2025
AbbVie Inc. stock logo
ABBV
AbbVie
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$251.00
10/3/2025
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$220.00 ➝ $251.00
(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$56.33B7.10$14.68 per share15.42$1.90 per share119.11
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$47.70B1.86$5.90 per share7.40$8.08 per share5.40
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$64.17B3.27$9.29 per share9.05$18.33 per share4.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.28B$2.10107.7716.191.476.45%699.66%13.64%10/31/2025 (Estimated)
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-$8.95B$2.4817.597.162.2510.58%80.04%14.69%10/30/2025 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$17.12B$6.4912.968.500.9425.79%41.05%16.55%10/30/2025 (Estimated)

Latest MRK, BMY, and ABBV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/31/2025Q3 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$3.26N/AN/AN/A$15.58 billionN/A
10/30/2025Q3 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.65N/AN/AN/A$11.75 billionN/A
10/30/2025Q3 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.37N/AN/AN/A$17.00 billionN/A
7/31/2025Q2 2025
AbbVie Inc. stock logo
ABBV
AbbVie
$3.24$2.97-$0.27$0.52$14.93 billion$15.42 billion
7/31/2025Q2 2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.07$1.46+$0.39$0.64$11.32 billion$12.27 billion
7/29/2025Q2 2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.03$2.13+$0.10$1.76$15.92 billion$15.81 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.562.90%N/A312.38%53 Years
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.485.68%N/A100.00%17 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.243.85%N/A49.92%14 Years

Latest MRK, BMY, and ABBV Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/5/2025
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.642.89%10/15/202510/15/202511/14/2025
9/17/2025
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.625.46%10/3/202510/3/202511/3/2025
7/22/2025
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.814%9/15/20259/15/202510/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
44.14
0.74
0.61
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.54
1.21
1.11
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.69
1.42
1.17

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.08%
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.07%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
55,0001.77 billion1.77 billionOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
34,1002.04 billion2.03 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.50 billion2.50 billionOptionable

Recent News About These Companies

Merck: A Golden Buying Opportunity
Zacks Research Analysts Lower Earnings Estimates for MRK
Leerink Partnrs Has Negative Outlook of MRK FY2025 Earnings
Merck & Co., Inc. (NYSE:MRK) Coverage Initiated at Citigroup
Zacks Research Issues Negative Outlook for MRK Earnings
Leerink Partnrs Issues Negative Forecast for MRK Earnings
Can $10,000 in Merck Stock Turn Into $50,000 by 2030?
Merck & Co. Earnings Preview: What to Expect
Vest Financial LLC Buys 20,838 Shares of Merck & Co., Inc. $MRK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AbbVie stock logo

AbbVie NYSE:ABBV

$226.31 -1.18 (-0.52%)
Closing price 03:59 PM Eastern
Extended Trading
$226.38 +0.07 (+0.03%)
As of 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$43.63 -0.17 (-0.39%)
Closing price 03:59 PM Eastern
Extended Trading
$43.64 +0.01 (+0.02%)
As of 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$84.11 -0.59 (-0.70%)
Closing price 03:59 PM Eastern
Extended Trading
$84.30 +0.19 (+0.22%)
As of 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.